Guselkumab in moderate-severe psoriasis: effectiveness assessment
- At: Seville (Spain) (2022)
- Type: Poster
- Poster code: HPS-093
- By: ARAGóN GRACIA, Irene (Hospital Universitario Marqués de Valdecilla, Spain)
- Co-author(s): Mrs Irene Aragón Gracia, Hospital Pharmacist (Hospital Universitario Marqués de Valdecilla, Santander, Spain)
Ms Lorenzo Perez-Periañez Orrillo, Hospital Pharmacist
Mrs Julia Sanchez Gundin, Hospital Pharmacist
Dr Susana Armesto Alonso, Dermatology
Mrs Clara Fernandez Martinez, Hospital Pharmacist
Mrs Rosana Lucia Rey Montalban, Hospital Pharmacist
Mrs Marta Valero Dominguez, Hospital Pharmacist
Guselkumab is a human IgG1λ monoclonal antibody that binds selectively to the IL-23, a regulatory cytokine, affects the differentiation, expansion, and survival of T cell subsets and innate immune cell subsets, which represent sources of effector cytokines.
To evaluate the effectiveness of guselkumab at week 12 in a cohort.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.